Table 2.
mpMRI findings in relation to PI-QUAL score
| PI-QUAL 1–2 (n = 40) |
PI-QUAL 3 (n = 57) |
PI-QUAL 4–5 (n = 254) |
p value | |
|---|---|---|---|---|
| PIRADS v2.1 score, n (%) | 0.011 | |||
| PI-RADS <3 | 2 (5) | 0 | 1 (0.4) | |
| PI-RADS 3 | 5 (12.5) | 3 (5.3) | 13 (5.1) | |
| PI-RADS 4 | 22 (55) | 30 (52.6) | 118 (46.5) | |
| PI-RADS 5 | 11 (27.5) | 24 (42.1) | 122 (48.0) | |
| mpMRI staging | 0.015 | |||
| T stage, n (%) | ||||
| mrT2 | 39 (97.5) | 47 (82.5) | 187 (73.6) | |
| mrT3a | 1 (2.5) | 8 (14.0) | 55 (21.7) | |
| mrT3b | 0 (0) | 2 (3.5) | 12 (4.7) | |
| N stage, n (%) | 0.881 | |||
| N0 | 38 (95.0) | 55 (96.5) | 243 (95.7) | |
| N1 | 2 (5.0) | 2 (3.5) | 11 (4.3) | |
| EPE, n (%) | ||||
| No EPE | 31 (77.5) | 34 (59.6) | 118 (46.5) | 0.001 |
| Early EPE | 9 (22.5) | 14 (24.6) | 75 (29.5) | 0.54 |
| Late EPE | 0 | 9 (15.8) | 61 (24.0) | 0.001 |
| Median ROI size, mm (IQR) | 12.5 (10.5–17.5) | 13.0 (10–16) | 13 (10–17) | 0.827 |
| Targets, n (%) | 0.04 | |||
| Unique | 34 (85) | 38 (66.7) | 165 (65.0) | |
| Multiple | 6 (15) | 19 (33.3) | 89 (35.0) |
EPE = extraprostatic extension; IQR = interquartile range; mpMRI = multiparametric magnetic resonance imaging; PI-QUAL = Prostate Imaging Quality score (nondiagnostic, PI-QUAL 1–2; sufficient, PI-QUAL 3; optimal, PI-QUAL 4–5); PI-RADS = Prostate Imaging-Reporting and Data System; ROI = region of interest.